Lineage Cell Therapeutics (LCTX) EBT Margin (2010 - 2026)

Lineage Cell Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 1120.52% for Q1 2026.

• In Q1 2026, EBT Margin fell 66713.0% year-over-year to 1120.52%; the TTM figure through Mar 2026 stood at 457.19% (down 26012.0% YoY), while the FY2025 annual figure was 471.61%, down 27599.0% from the prior year.
• EBT Margin for Q1 2026 stood at 1120.52%, down from 103.77% in the prior quarter.
• The five-year high for EBT Margin was 79.41% in Q3 2024, with the low at 1120.52% in Q1 2026.
• The 5-year median for EBT Margin is 260.14% (2023), against an average of 357.99%.
• The sharpest annual moves came in 2022 and 2026: EBT Margin surged 82077 bps in 2022, then plunged 66713 bps in 2026.
• Lineage Cell Therapeutics' EBT Margin stood at 332.22% in 2022, then soared by 32 bps to 225.77% in 2023, then surged by 50 bps to 113.32% in 2024, then increased by 8 bps to 103.77% in 2025, then tumbled by 980 bps to 1120.52% in 2026.
• Business Quant data shows LCTX's EBT Margin at 1120.52% in Q1 2026, 103.77% in Q4 2025, and 512.01% in Q3 2025.